Kilitch Drugs India Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Kilitch Drugs (India) Ltd is ₹ 152 as of 05 May 15:30 . The P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 years The Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 years The revenue of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 55.34 crore as compare to the Sep '25 revenue of ₹ 55.58 crore. This represent the decline of -0.43% The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The ebitda of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 7.68 crore as compare to the Sep '25 ebitda of ₹ 11.7 crore. This represent the decline of -34.36% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 4.32 crore over 7 quarters. This represents a CAGR of 714.53% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Kilitch Drugs (India) Ltd or Sanjivani Paranteral Ltd?

Market cap of Kilitch Drugs (India) Ltd is 531 Cr while Market cap of Sanjivani Paranteral Ltd is 205 Cr

What are the key factors driving the stock performance of Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd?

The stock performance of Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd?

As of May 5, 2026, the Kilitch Drugs (India) Ltd stock price is INR ₹152.0. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹167.5.

How do dividend payouts of Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Kilitch Drugs (India) Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.